Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02723955 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 829
- Enrollment target
NCT02723955 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 829 participants.
The verdict
NCT02723955, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 829 participants
- Enrollment target
Study Summary
GSK3359609 is an anti-Inducible T cell Co-Stimulator (ICOS) receptor agonist antibody intended for the treatment of cancers of different histology. This is a first-time-in-human (FTIH), open-label, multicenter study designed to investigate the safety, pharmacology, and preliminary antitumor activity in participants with selected, advanced or recurrent solid tumors with the aim to establish recommended dose(s) of GSK3359609 for further exploration as monotherapy and in combination with pembrolizumab or chemotherapy regimens. The study is comprised of two primary parts, each composed of two phases: Part 1: GSK3359609 monotherapy with Part 1A as dose escalation phase and Part 1B as cohort expansion phase; Part 2: GSK3359609 combination therapy with Part 2A pembrolizumab or GSK3174998 or chemotherapy or pembrolizumab plus chemotherapy or dostarlimab plus cobolimab or Bintrafusp alfa combination dose escalation phase and Part 2B expansion phase with pembrolizumab. The primary objective of the study is to determine the safety, tolerability, maximum tolerated dose or the maximum administered dose of GSK3359609 alone or in combination.
Interventions
- DRUG Pembrolizumab
- DRUG Docetaxel
- DRUG Pemetrexed
- DRUG GSK3174998
- DRUG feladilimab (GSK3359609)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 829 participants |
| Start Date | 2016-06-23 |
| Est. Completion | 2023-07-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02723955
The ClinicalTrials.gov registry entry for NCT02723955 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 829 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT02723955 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02723955 about?
NCT02723955 is a clinical study titled "Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)". GSK3359609 is an anti-Inducible T cell Co-Stimulator (ICOS) receptor agonist antibody intended for the treatment of cancers of different histology. This is a first-time-in-human (FTIH), open-label, multicenter study designed to investigate the safety, pharmacology, and preliminary antitumor activity...
What is the current status of trial NCT02723955?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 829 participants. The study started on 2016-06-23. Estimated completion is 2023-07-05.
What interventions are being tested in trial NCT02723955?
The interventions under investigation include: Pembrolizumab (DRUG), Docetaxel (DRUG), Pemetrexed (DRUG), GSK3174998 (DRUG), feladilimab (GSK3359609) (DRUG).
Who is sponsoring clinical trial NCT02723955?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.